Turkmenistan Becomes the Seventh Country that Approves BIBP’s COVID-19 Vaccine for Registration and Marketing

On July 6 local time, Turkmenistan (a Central Asian country) announced that it has approved the application for registration of the Inactivated COVID-19 Vaccine (Vero Cell) developed and produced by Beijing Institute of Biological Products Co., Ltd. (BIBP), China National Biotec Group Company Limited (CNBG), Sinopharm (hereinafter referred to as “BIBP’s COVID-19 vaccine”), making it the seventh country in the world that approves BIBP’s COVID-19 vaccine for registration and marketing. Earlier, the vaccine has been approved for registration or conditional marketing in the UAE, Bahrain, China, Bolivia, Seychelles and Thailand, respectively.

      Up until now, BIBP’s COVID-19 vaccine has been approved for emergency use or market access in 85 countries, regions and international organizations, received the procurement requests from more than 100 countries, and vaccination has covered 196 country population. It is also the first COVID-19 vaccine in China that has been included into Emergency Use Listing (EUL) by WHO and granted the GMP certification by EU. With the completion and production of the world’s largest COVID-19 vaccine production base in BIBP, CNBG, the overall annual production capacity of BIBP's COVID-19 vaccine has exceeded 5 billion doses, enabling China to contribute more strength to the global fight against the COVID-19 and the building of a community of common health for mankind, to a greater extent and in a broader scope.

      BIBP's COVID-19 vaccines provided by the Chinese government have arrived in Turkmenistan on March 6. On June 27, Turkmenistan’s President Gurbanguly Berdymukhamedov signed a decree to purchase 1.5 million doses of BIBP’s COVID-19 vaccine, in order to further strengthen the country’s public health and prevent infectious diseases.